Plain-English translation of NCT05794399 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a heart attack, some patients develop blood clots in the heart's main pumping chamber. This trial is testing whether a newer medication called works as well as —an older blood thinner—to prevent these clots from causing strokes or other serious problems. The study will help doctors decide which medication is safer and more effective for patients in Nepal and similar settings.
In Nepal, many patients arrive at the hospital too late for immediate clot-removal procedures, which makes blood clots in the heart more likely to form. While has been used for decades, the newer medication may be easier to take (no blood tests needed, fewer food restrictions) and just as safe. This trial will provide evidence to guide treatment choices for patients like you.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either or . If you receive , you will need regular blood tests to adjust your dose; if you receive , you will take a fixed dose with minimal monitoring. You will be followed for at least 12 months while taking your assigned medication to check how well it works and whether you experience any side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
Nepal
Post-approval monitoring
Sponsor
Shahid Gangalal National Heart Centre
Enrollment target
~196 participants
Started
June 2023
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dipanker Prajapati, MBBS, MD
Shahid Gangalal National Heart Centre
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.